安体舒通对慢性充血性心力衰竭患者QT离散度的影响

目的观察安体舒通对慢性充血性心力衰竭患者QT离散度(QTd)的影响,探讨其临床应用价值。方法采用随机、对照方法,设立安体舒通干预组及常规治疗组,测定两组用药前及用药1月后的QTd、校正QT离散度(QTcd)、血钾、血镁、血钠和肌酐。同时测定正常对照者的QTd及QTcd。结果心力衰竭组QTd、QTcd较对照组明显延长,差异有显著性(p<0.01);安体舒通干预组治疗后QTd、QTcd较治疗前显著下降(p<0.01):安体舒通干预组血清钾、镁治疗后较治疗前明显升高(p<0.01),肌酐轻度减低但差异无显著性(p>0.05)。结论安体舒通可降低心衰患者的QTd、QTcd。

The effect of spironolactone on QT dispersion in chronic heart failure

Objective The study was designed to observe the effects of spironolactone on QT dispersion in chronic heart failure (CHF),and explore its clinical benefits. Method Selecting a comparative,randomized way to measure QT dispersion (QTd),corrected QT dispersion(QTcd), serum magnesium and potassium,plasma sodium and creatinine in patients with CHF after they have received a month spironolactone therapy,while QTd,QTcd of healthy adults population having been measured. Results QTd and QTcd were greater in patients with CHF than in heathy subjects (p<0.01), spironolactone prominently improved QTd and QTcd in CHF; after one month treatment, spironolactone caused a small but significant rise in serum potassium and magnesium,while obviously decrease in no-spironolactone group,those level after treatment was particularly different (p<0.01,respectively). Conclusion Spironolactone can reduce QT dispersion and corrected QT dispersion in CHF.